Bubble Intelligence

Market Intelligence For The New Regime

REGENERON PHARMACEUTICALS, INC.
REGNregeneron.com
Latest Filing: Apr 29, 2026 • 25 Total Filings
Total Assets
2026
$40.87B
Total Revenue
2026
$3.61B
Net Income
2026
$727.20M
Operating Cash Flow
2026
$1.08B
Filing Year:
2025
Only 2025 data available
Data Source:
Showing data from all document types
Filters:
located inlocated incompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes withcompetes with
REGENERON PHARMACEUTICALS, INC.
Ticker: REGN
Unknown Region
2 suppliers
Catalent Indiana, LLC
contract_manufacturer
⚠ Critical
Novo Nordisk A/S
contract_manufacturer
⚠ Critical
AstraZeneca
Collaboration partner, not a competitor in this context
Merck
Genentech/Roche's
Competition for marketed products
Novartis
Competition for marketed products
Biogen Inc.
Competition for marketed products
Amgen
Competition for marketed products
Genentech/Roche
EYLEA HD and EYLEA compete with their VEGF inhibitors
Major Competitor
Bristol-Myers Squibb
Libtayo competes with Opdivo
Major Competitor
Roche
Libtayo competes with Tecentriq
Major Competitor
Sun Pharma
Libtayo competes with Unloxcyt
Major Competitor
React Flow
Legend:
Company
Critical Supplier
Significant Supplier
Standard Supplier
Major Competitor
Emerging Competitor
Competitor
Regional Supplier Concentration
0 regions with known supplier geography · 2 suppliers without location data
Risk:LowModerateElevatedHigh
2 suppliers · no geography